Metabolic Interventions in Oncology: From Pharmacological Agents to Dietary Strategies

The metabolism–cancer axis is currently at a critical inflection point. A landmark August 2025 JAMA Oncology study reported a 17% reduction in overall cancer incidence among GLP-1 receptor agonist users, with particularly marked effects in endometrial and ovarian cancers. In parallel, the 2024 FDA approval of vorasidenib for IDH-mutant glioma has validated biomarker-guided metabolic targeting in oncology. Conversely, recent Phase III failures of metformin trials underscore important translational challenges. At the same time, patient interest in dietary and metabolic interventions continues to outpace the available evidence base. This Research Topic aims to synthesize rapidly evolving data on cancer metabolism, dietary and pharmacological interventions, and bridge mechanistic insights with clinical practice. The primary objective is to elucidate the mechanisms underlying cancer risk modulation by metabolic drugs, reasons for translational failure despite preclinical promise, biomarker strategies for patient selection, evidence standards for dietary interventions in oncology, and rational combinations with immunotherapy.To gather further insights in the field of metabolic interventions in oncology, we welcome articles that address, but are not limited to, the following themes: the boundaries encompass preclinical, translational, and clinical aspects of metabolic manipulation in cancer, while excluding research unrelated to metabolic interventions. Topics of interest include, but are not limited to:● Pharmacological metabolic interventions, including GLP-1 receptor agonists, metformin, SGLT2 inhibitors, IDH inhibitors, lipid and amino-acid metabolism targeting, and metabolic agents used in supportive care● Dietary and nutritional strategies such as ketogenic, plant-based and Mediterranean diets, nutritional supplements, and microbiome-targeted approaches● Metabolic supportive care, including cancer cachexia, metabolic cardio-oncology, and diabetes management during cancer treatment.Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal. Topic editors: Salvatore CORTELLINO, Antonino De Lorenzo, CANIO MARTINELLI Source: https://www.frontiersin.org/research-topics/78200/metabolic-interventions-in-oncology-from-pharmacological-agents-to-dietary-strategies